Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline

[Guidelines for iron chelation therapy in thalassemia in China (2025)]

[Article in Chinese]
Committee of Thalassemia Prevention and Treatment, China Maternal and Child Health Association et al. Zhongguo Dang Dai Er Ke Za Zhi. .

Abstract
in English, Chinese

Iron overload is a major complication of thalassemia, clinically manifested as heart failure, liver cirrhosis, diabetes, growth and development retardation, and delayed sexual development, with severe cases leading to death. Standardized iron chelation therapy is essential to ensure long-term and high-quality survival for patients. This guideline provides recommendations on methods for detecting iron overload, the timing for initiating iron chelation therapy, treatment strategies for transfusion-dependent and non-transfusion-dependent thalassemia, and special circumstances regarding iron chelation therapy, serving as a reference for iron chelation treatment in thalassemia.

铁过载是地中海贫血的主要并发症，临床表现为心力衰竭、肝硬化、糖尿病、生长发育迟缓、性发育延迟等，严重者导致死亡。规范的祛铁治疗才能保证患者长期和高质量生存。该指南对铁过载的检测方法、祛铁治疗的启动时机、输血依赖型地中海贫血和非输血依赖型地中海贫血祛铁治疗策略、特殊情况下的祛铁治疗策略等提出了推荐意见，为地中海贫血祛铁治疗提供参考。.

Keywords: Guideline; Iron chelation therapy; Iron overload; Thalassemia.

PubMed Disclaimer

Conflict of interest statement

所有作者声明无利益冲突。

Figures

图1
图1. 文献筛选流程
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Musallam KM, Lombard L, Kistler KD, et al. . Epidemiology of clinically significant forms of alpha- and beta-thalassemia: a global map of evidence and gaps[J]. Am J Hematol, 2023, 98(9): 1436-1451. - PubMed
    1. Lai K, Huang G, Su L, et al. . The prevalence of thalassemia in the mainland of China: evidence from epidemiological surveys[J]. Sci Rep, 2017, 7(1): 920. DOI: 10.1038/s41598-017-00967-2. - DOI - PMC - PubMed
    1. Yin A, Li B, Luo M, et al. . The prevalence and molecular spectrum of α- and β-globin gene mutations in 14 332 families of Guangdong Province, China[J]. PLoS One, 2014, 9(2): e89855. DOI: 10.1371/journal.pone.0089855. - DOI - PMC - PubMed
    1. Ansharullah BA, Sutanto H, Romadhon PZ. Thalassemia and iron overload cardiomyopathy: pathophysiological insights, clinical implications, and management strategies[J]. Curr Probl Cardiol, 2025, 50(1): 102911. DOI: 10.1016/j.cpcardiol.2024.102911. - DOI - PubMed
    1. Coates TD. Management of iron overload: lessons from transfusion-dependent hemoglobinopathies[J]. Blood, 2025, 145(4): 359-371. DOI: 10.1182/blood.2023022502. - DOI - PubMed

Substances